These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

792 related articles for article (PubMed ID: 15564564)

  • 1. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
    Collin-Osdoby P
    Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.
    Sattler AM; Schoppet M; Schaefer JR; Hofbauer LC
    Calcif Tissue Int; 2004 Jan; 74(1):103-6. PubMed ID: 14523602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoclast precursors, RANKL/RANK, and immunology.
    Xing L; Schwarz EM; Boyce BF
    Immunol Rev; 2005 Dec; 208():19-29. PubMed ID: 16313338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
    Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
    Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
    Mochizuki S; Kiyokawa A; Nagayama Y
    Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    Kiechl S; Werner P; Knoflach M; Furtner M; Willeit J; Schett G
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):801-11. PubMed ID: 17173497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    D'Amelio P; Isaia G; Isaia GC
    J Endocrinol Invest; 2009; 32(4 Suppl):6-9. PubMed ID: 19724159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.
    Ueland T; Yndestad A; Øie E; Florholmen G; Halvorsen B; Frøland SS; Simonsen S; Christensen G; Gullestad L; Aukrust P
    Circulation; 2005 May; 111(19):2461-8. PubMed ID: 15883214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical implications of new insights into the regulation of bone resorption].
    Lems WF; Bijlsma JW
    Ned Tijdschr Geneeskd; 2005 Jul; 149(30):1664-7. PubMed ID: 16104110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N; Colla S; Rizzoli V
    Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].
    Ferrer Cañabate J; Tovar I; Martínez P
    An Med Interna; 2002 Aug; 19(8):385-88. PubMed ID: 12244784
    [No Abstract]   [Full Text] [Related]  

  • 12. Crystal structure of RANK ligand involved in bone metabolism.
    Ito S; Hata T
    Vitam Horm; 2004; 67():19-33. PubMed ID: 15110169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?
    Dovio A; Data V; Angeli A
    J Endocrinol Invest; 2005; 28(10 Suppl):14-22. PubMed ID: 16550717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatic diseases: the effects of inflammation on bone.
    Walsh NC; Crotti TN; Goldring SR; Gravallese EM
    Immunol Rev; 2005 Dec; 208():228-51. PubMed ID: 16313352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization.
    Sandberg WJ; Yndestad A; Øie E; Smith C; Ueland T; Ovchinnikova O; Robertson AK; Müller F; Semb AG; Scholz H; Andreassen AK; Gullestad L; Damås JK; Frøland SS; Hansson GK; Halvorsen B; Aukrust P
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):857-63. PubMed ID: 16424351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Ann N Y Acad Sci; 2006 Apr; 1068():225-33. PubMed ID: 16831922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.
    Blair JM; Zhou H; Seibel MJ; Dunstan CR
    Nat Clin Pract Oncol; 2006 Jan; 3(1):41-9. PubMed ID: 16407878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
    Tanaka S; Nakamura K; Takahasi N; Suda T
    Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
    Anandarajah AP; Schwarz EM
    J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.